

Melinta Therapeutics Inc - Strategic SWOT Analysis Review

<https://marketpublishers.com/r/M20CD7DDBE7EN.html>

Date: December 2021

Pages: 32

Price: US\$ 125.00 (Single User License)

ID: M20CD7DDBE7EN

Abstracts

Melinta Therapeutics Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company's history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company's key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – GlobalData's summarization of the company's business strategy.

SWOT analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

Highlights

Melinta Therapeutics Inc (Melinta) is a biopharmaceutical company that focuses on the development of novel anti-infectives for the treatment of various bacterial infections. Its marketed portfolio encompasses antibiotics for the treatment of serious bacterial infections including acute bacterial skin and skin structure infections (ABSSSI), complicated urinary tract infections (cUTI), and for the prevention and treatment of other serious infections that are caused by susceptible bacteria. The company is also evaluating delafloxacin for the treatment of serious community-acquired bacterial pneumonia (CABP), meropenem and vaborbactam, oritavancin, and minocycline. Melinta's products and pipeline candidates are built on ribosome platform licensed from Yale University. Melinta is headquartered in New Haven, Connecticut, the US.

Melinta Therapeutics Inc Key Recent Developments

Oct 25,2021: Melinta Therapeutics Announces Appointment of Doug Girgenti as Vice President of Drug Development

Jul 06,2021: Melinta Therapeutics Announces Appointment of Jisoo Park as Head of Business Development, M&A and Strategy

Jun 29,2021: Melinta Therapeutics Announces Appointment of Susan Blum as Chief Financial Officer

Mar 29,2021: Melinta Therapeutics Announces Appointment of John Harlow as Chief Commercial Officer

Nov 16,2020: Melinta Therapeutics announces appointment of Kristen Allgor as Chief Human Resources Officer

Reasons to Buy

Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.

Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services and business strategy.

Understand and respond to your competitors' business structure and strategies with GlobalData's detailed SWOT analysis. In this, the company's core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.

Examine potential investment and acquisition targets with this report's detailed insight into the company's strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

Contents

SECTION 1 - ABOUT THE COMPANY

Melinta Therapeutics Inc - Key Facts
Melinta Therapeutics Inc - Key Employees
Melinta Therapeutics Inc - Key Employee Biographies
Melinta Therapeutics Inc - Major Products and Services
Melinta Therapeutics Inc - History
Melinta Therapeutics Inc - Company Statement
Melinta Therapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Melinta Therapeutics Inc - Business Description
Melinta Therapeutics Inc - Corporate Strategy
Melinta Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Melinta Therapeutics Inc - Strengths
Melinta Therapeutics Inc - Weaknesses
Melinta Therapeutics Inc - Opportunities
Melinta Therapeutics Inc - Threats
Melinta Therapeutics Inc - Key Competitors

SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Melinta Therapeutics Inc, Recent Deals Summary

SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

Oct 25, 2021: Melinta Therapeutics Announces Appointment of Doug Girgenti as Vice President of Drug Development

Jul 06, 2021: Melinta Therapeutics Announces Appointment of Jisoo Park as Head of Business Development, M&A and Strategy

Jun 29, 2021: Melinta Therapeutics Announces Appointment of Susan Blum as Chief Financial Officer

Mar 29, 2021: Melinta Therapeutics Announces Appointment of John Harlow as Chief Commercial Officer

Nov 16, 2020: Melinta Therapeutics announces appointment of Kristen Allgor as Chief Human Resources Officer

Aug 03, 2020: Melinta Therapeutics announces appointment of Christine Ann Miller as President and Chief Executive Officer

Apr 20, 2020: Melinta Therapeutics successfully completes financial restructuring

Feb 13, 2020: Melinta Therapeutics announces court approval of chapter 11 bidding procedures

SECTION 5 – APPENDIX

Methodology

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Melinta Therapeutics Inc, Key Facts

Melinta Therapeutics Inc, Key Employees

Melinta Therapeutics Inc, Key Employee Biographies

Melinta Therapeutics Inc, Major Products and Services

Melinta Therapeutics Inc, History

Melinta Therapeutics Inc, Subsidiaries

Melinta Therapeutics Inc, Key Competitors

Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Melinta Therapeutics Inc, Recent Deals Summary

List Of Figures

LIST OF FIGURES

Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: Melinta Therapeutics Inc - Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/M20CD7DDBE7EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M20CD7DDBE7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970